temozolomide has been researched along with ritonavir in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 7 (87.50) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Halatsch, ME; Karpel-Massler, G; Kast, RE | 1 |
Kast, RE | 1 |
Coveñas, R; Kast, RE; Lladó, S; Muñoz, M; Ramiro, S; Toro, S | 1 |
Ahmad, A; Brüstle, O; Darkwah Oppong, M; Dobersalske, C; Fröhlich, H; Glas, M; Jabbarli, R; Kebir, S; Pierscianek, D; Rauschenbach, L; Reinartz, R; Scheffler, B; Simon, M; Sure, U; Till, A; Ullrich, V; Wieland, A | 1 |
1 review(s) available for temozolomide and ritonavir
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
7 other study(ies) available for temozolomide and ritonavir
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Artesunate; Auranofin; Brain Neoplasms; Captopril; Celecoxib; Dacarbazine; Disulfiram; Glioblastoma; Humans; Itraconazole; Molecular Targeted Therapy; Morpholines; Neoplasm Recurrence, Local; Pyrazoles; Ritonavir; Sertraline; Signal Transduction; Sulfonamides; Temozolomide; Treatment Outcome | 2014 |
The role of interleukin-18 in glioblastoma pathology implies therapeutic potential of two old drugs-disulfiram and ritonavir.
Topics: Antineoplastic Agents; Dacarbazine; Disulfiram; Glioblastoma; Humans; Interleukin-18; Ritonavir; Temozolomide | 2015 |
Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.
Topics: Antiemetics; Antineoplastic Agents, Alkylating; Apoptosis; Aprepitant; Brain Neoplasms; Cell Proliferation; Dacarbazine; Glioblastoma; HIV Protease Inhibitors; Humans; Immunoenzyme Techniques; Morpholines; Ritonavir; Temozolomide; Tumor Cells, Cultured | 2016 |
Drug repositioning of antiretroviral ritonavir for combinatorial therapy in glioblastoma.
Topics: Adult; Anti-Retroviral Agents; Antineoplastic Agents; Autophagy; Cell Line; Drug Repositioning; Drug Therapy, Combination; Endoplasmic Reticulum Stress; Female; Glioblastoma; Humans; Male; Neoplasm Recurrence, Local; Ritonavir; Temozolomide | 2020 |